Screening program for heart and metabolic health in breast cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This program aims to implement a cardiometabolic screening initiative for women who have survived early-stage breast cancer. It focuses on identifying risk factors such as prediabetes, diabetes, dyslipidemia, and cardiovascular disease. Participants will undergo routine screening tests and be directed to community and institutional resources for managing these risks. The study will assess the prevalence of these conditions and track improvements in health outcomes over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of early stage breast cancer
* Completed local and/or systemic therapy at least 3 months ago
* Receiving medical oncology care at through the breast cancer clinics at Johns Hopkins Medical Institute, including the Sidney Kimmel Comprehensive Cancer Center in Baltimore MD and Green Spring Station in Lutherville-Timonium MD, and Sibley Memorial Hospital in Washington D.C.
* Read and speak English

Exclusion Criteria:

* Metastatic breast cancer

Where it's running

• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Jennifer Sheng, M.D. — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Study coordinator: Hopkins Breast Trials
• Email: HopkinsBreastTrials@jhmi.edu
• Phone: 410-614-1361

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using blood-based tumor DNA (ctDNA) to find leftover breast cancer after treatment

  This research will test whether a simple blood test that looks for tiny bits of tumor DNA can tell if people treated for breast cancer (including HR+/HER2-, HER2+, and triple-negative) still have leftover cancer or are at risk of recurrence.

  Recruiting at 16 sites Tempus AI · Birmingham, Alabama and 15 other locations · NCT07211178

• Switching aromatase inhibitors versus guideline-based side-effect care to help with AI side effects

  This test tries switching one aromatase inhibitor to another versus using guideline-based side-effect care to see which helps postmenopausal women with early-stage ER-positive breast cancer stay on their hormone therapy.

  Recruiting Phase 2 Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT07071038

• Radiation therapy for early-stage breast cancer using a shorter treatment schedule

  This study is testing a shorter radiation treatment schedule for women 50 and older with early-stage breast cancer to see if it is safe and effective while reducing the number of visits needed.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06902311

• Using Biolosion with standard therapy to treat triple-negative breast cancer

  This study is testing if adding a new oral probiotic called Biolosion to standard treatment can help women with locally advanced triple-negative breast cancer have better outcomes.

  Recruiting Phase 2 Sun Yat-sen University · Lanzhou, Gansu and 4 other locations · NCT06768931

• Water-only fasting to improve chemotherapy for early-stage breast cancer

  This study is testing if fasting for 24-48 hours can help make chemotherapy work better and be easier to tolerate for people with early-stage breast cancer.

  Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Washington D.C., District of Columbia · NCT06536881

• Precision neoadjuvant therapy for operable breast cancer

  This study is testing if a personalized treatment approach using new drugs for operable breast cancer can work better than standard chemotherapy alone.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05582499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.